World leading research-based pharmaceutical and healthcare company, GlaxoSmithKline (GSK), today announced its partnership with the University of Sharjah to help encourage women in scientific research through the sponsorship of ‘The Second Forum on Women in Scientific Research’.

The forum is set to take place on 26 August 2021 and will be open to applications from any female student and female researcher from any university in the UAE. Female researchers will be able to submit their projects across categories such as health sciences, pharmacy, medicine and dentistry to help address issues and challenges in the field of scientific research.  GSK will be funding 50,000 AED in award money for winning projects to support female researchers and help bring their innovation to life.

Commenting on the partnership, Gizem Akalin, Ph. D, Vice President and General Manager – GSK Gulf, said: “We are excited to partner with the University of Sharjah to support female researchers in the UAE and foster innovation. GSK’s strategy is to help create opportunities for innovation and research and contribute positively to the medical community. Gender diversity is also a core ambition at GSK. As such, we are proud to be able to champion the efforts of women and provide equal opportunities for female researchers in the healthcare sector.”

Professor Maamar Bettayeb, Vice Chancellor for Research and Graduate Studies from the University of Sharjah, said: “With a reputation as a leader in innovation and research and development, the University of Sharjah is delighted to have GSK as a partner for this forum. We are very much looking forward to engaging with talented researchers about their projects. We hope that the forum will further encourage women to pursue their passion for scientific research, and we aim to increase the participation of women in medical and scientific research.”

In addition to the ‘The Second Forum on Women in Scientific Research’, GSK and the University of Sharjah are planning to expand educational opportunities for researchers and collaborate closely on future research.  

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.